Egyptian International Pharmaceutical Investments (CAI:PHAR) EV-to-Revenue : 1.90 (As of Apr. 30, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Egyptian International Pharmaceutical Investments's enterprise value is E£9,940 Mil. Egyptian International Pharmaceutical Investments's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was E£5,232 Mil. Therefore, Egyptian International Pharmaceutical Investments's EV-to-Revenue for today is 1.90.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's EV-to-Revenue or its related term are showing as below:

CAI:PHAR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.61 Med: 2.41 Max: 9.64
Current: 1.9

During the past 13 years, the highest EV-to-Revenue of Egyptian International Pharmaceutical Investments was 9.64. The lowest was 0.61. And the median was 2.41.

CAI:PHAR's EV-to-Revenue is ranked better than
56.25% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.295 vs CAI:PHAR: 1.90

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Egyptian International Pharmaceutical Investments's stock price is E£38.56. Egyptian International Pharmaceutical Investments's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was E£37.52. Therefore, Egyptian International Pharmaceutical Investments's PS Ratio for today is 1.03.

Egyptian International Pharmaceutical Investments EV-to-Revenue Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EV-to-Revenue Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1.76

1.22

1.64

1.51

1.84

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.51	1.53	0.65	1.88	1.84

Competitive Comparison of Egyptian International Pharmaceutical Investments's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's EV-to-Revenue falls into.

Egyptian International Pharmaceutical Investments EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Egyptian International Pharmaceutical Investments's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	9940.197	/	5231.666
	=	1.90

Egyptian International Pharmaceutical Investments's current Enterprise Value is E£9,940 Mil.
Egyptian International Pharmaceutical Investments's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£5,232 Mil.

Egyptian International Pharmaceutical Investments (CAI:PHAR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Egyptian International Pharmaceutical Investments's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	38.56	/	37.516
	=	1.03

Egyptian International Pharmaceutical Investments's share price for today is E£38.56.
Egyptian International Pharmaceutical Investments's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£37.52.

Egyptian International Pharmaceutical Investments EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.